Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRX AcelRx Pharmaceuticals		$0.77	$0.43 ▼ $2.78	$14.58M	0.52	137,683 shs	243,500 shs
ELYM Eliem Therapeutics	$2.25 +11.4%	$1.45	$2.35 ▼ $11.55	$66.94M	-0.39	486,688 shs	878,696 shs
OSTX OS Therapies	$2.40 +9.6%	$1.80	$1.12 ▼ $7.00	$75.90M	N/A	735,302 shs	1.79 million shs
PYRGF PyroGenesis Canada	$0.21 -9.2%	$0.31	$0.21 ▼ $0.71	$39.57M	0.83	13,012 shs	9,763 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRX AcelRx Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
ELYM Eliem Therapeutics	-4.27%	+25.47%	+33.77%	+66.94%	-66.28%
OSTX OS Therapies	+1.86%	+16.49%	+29.59%	+43.14%	-41.60%
PYRGF PyroGenesis Canada	+1.66%	-15.12%	-27.05%	-29.25%	-61.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRX AcelRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	2.2756 of 5 stars	3.7	0.0	0.0	0.0	2.2	0.8	0.6
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRX AcelRx Pharmaceuticals	0.00	N/A	N/A	N/A
ELYM Eliem Therapeutics	0.00	N/A	N/A	N/A
OSTX OS Therapies	3.40	Buy	$18.00	650.00% Upside
PYRGF PyroGenesis Canada	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ACRX, PYRGF, OSTX, and ELYM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/14/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/30/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRX AcelRx Pharmaceuticals	$1.77M	0.00	N/A	N/A	$2.65 per share	0.00
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	$3.90 per share	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	$9.14M	4.33	N/A	N/A	($0.01) per share	-21.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRX AcelRx Pharmaceuticals	$47.76M	-$2.23	N/A	N/A	N/A	N/A	-81.54%	-46.02%	N/A
ELYM Eliem Therapeutics	-$35.12M	-$0.53	N/A	∞	N/A	N/A	-47.03%	-45.97%	N/A
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A
PYRGF PyroGenesis Canada	-$21.12M	-$0.03	N/A	∞	N/A	-115.14%	N/A	-60.81%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRX AcelRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRX AcelRx Pharmaceuticals	N/A	4.04	4.04
ELYM Eliem Therapeutics	N/A	60.41	60.41
OSTX OS Therapies	N/A	0.76	0.76
PYRGF PyroGenesis Canada	N/A	0.60	0.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRX AcelRx Pharmaceuticals	19.79%
ELYM Eliem Therapeutics	69.76%
OSTX OS Therapies	N/A
PYRGF PyroGenesis Canada	0.03%

Insider Ownership

Company	Insider Ownership
ACRX AcelRx Pharmaceuticals	3.00%
ELYM Eliem Therapeutics	4.70%
OSTX OS Therapies	13.80%
PYRGF PyroGenesis Canada	47.68%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRX AcelRx Pharmaceuticals	19	16.95 million	16.44 million	Optionable
ELYM Eliem Therapeutics	9	29.75 million	28.35 million	Not Optionable
OSTX OS Therapies	N/A	31.62 million	N/A	N/A
PYRGF PyroGenesis Canada	90	187.53 million	96.34 million	No Data

ACRX, PYRGF, OSTX, and ELYM Headlines

Recent News About These Companies

PyroGenesis Announces Second Quarter 2025 Results

August 6, 2025 | globenewswire.com

PyroGenesis Signs Additional Contract with Constellium to Advance Aluminum Furnace Electrification Using Plasma Torch Technology

August 5, 2025 | globenewswire.com

PyroGenesis Canada (NASDAQ:PYRGF) Stock Price Down 1% - Here's What Happened

August 3, 2025 | marketbeat.com

PyroGenesis Schedules Second Quarter 2025 Financial Results and Business Update Conference Call

August 1, 2025 | globenewswire.com

PyroGenesis Receives Initial Contract for Titanium Metal Powder from European Additive Manufacturing Company

July 31, 2025 | globenewswire.com

PyroGenesis Confirms Third-Party SEM Analysis Supports Pilot-Scale Fumed Silica Morphology Consistent with Commercial-Grade Fumed Silica

July 28, 2025 | globenewswire.com

PyroGenesis Announces Completion of Coke-Oven Gas Valorization and Hydrogen Production Project for Tata Steel

July 15, 2025 | globenewswire.com

PyroGenesis Improves Fumed Silica Quality, Purity, and Consistency Across Multiple Production Cycles

July 8, 2025 | globenewswire.com

PyroGenesis Signs $600,000 Contract Targeting Plastic Waste Management Problem in Europe

July 2, 2025 | globenewswire.com

PyroGenesis Reports Voting Results from 2025 Annual Meeting of Shareholders - Morningstar

June 29, 2025 | morningstar.comM

PyroGenesis Reports Voting Results from 2025 Annual Meeting of Shareholders

June 27, 2025 | globenewswire.com

PyroGenesis Confirms Verification of Fumed Silica Samples by Leading Global Supplier

June 12, 2025 | globenewswire.com

PyroGenesis Announces Extension to Term of Warrants

June 9, 2025 | globenewswire.com

High-Tech Micro Cap Rallies After Securing Boeing Supplier Status

May 29, 2025 | msn.com

PyroGenesis Confirms Receiving Accelerated Customer Request for Fumed Silica Samples

May 28, 2025 | globenewswire.com

PyroGenesis Confirms Production of Fumed Silica at Pilot Scale Following Independent Analysis

May 21, 2025 | globenewswire.com

PyroGenesis Confirms Successful Collection of Material from Fumed Silica Pilot Plant Baghouse

May 15, 2025 | globenewswire.com

PyroGenesis, Inc. (PYRGF) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

PyroGenesis Announces First Quarter 2025 Results

May 13, 2025 | globenewswire.com

PyroGenesis Provides Update on Fumed Silica Project

May 13, 2025 | globenewswire.com

PyroGenesis Closes $2,385,000 First Tranche in Previously Announced Loan

May 12, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRX, PYRGF, OSTX, and ELYM Company Descriptions

AcelRx Pharmaceuticals NASDAQ:ACRX

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

Eliem Therapeutics NASDAQ:ELYM

$2.25 +0.23 (+11.39%)

As of 08/20/2025

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

OS Therapies NYSE:OSTX

$2.40 +0.21 (+9.59%)

Closing price 04:00 PM Eastern

Extended Trading

$2.42 +0.02 (+1.04%)

As of 04:37 PM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

PyroGenesis Canada NASDAQ:PYRGF

$0.21 -0.02 (-9.25%)

As of 03:43 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time